Cardiovascular Devices MarketSize, Share & Industry Analysis, 2026-2034By DevicetypeBy ApplicationBy End-userBy Procedure TypeBy Distribution Channel

Cardiovascular devices are the diagnostic, monitoring, interventional, implantable and surgical instruments used to detect, treat and manage diseases of the heart and blood vessels, spanning products from ECG monitors and cardiac catheters to stents, pacemakers and heart valves. These devices are purchased primarily by hospitals, cardiology clinics, ambulatory surgical centers and, increasingly, by patients managing chronic cardiac conditions at home. Buyers range from hospital procurement committees selecting implantable and interventional technology for acute care to individual patients and caregivers purchasing home monitoring equipment through retail and online channels.

The global cardiovascular devices market is valued at USD 67.5 billion in 2025 and is set to reach USD 127.13 billion by 2034, a compound annual growth rate of 7.31% across the 2026-2034 forecast period. The study tracks the market across USD 49.5 billion in 2020, USD 64.6 billion in 2024, USD 72.3 billion in 2026 and USD 95.9 billion in 2030.

The devicetype mix shifts over the period. Interventional Devices is the largest line in 2025 at USD 20.25 billion, a 30% share, moving to USD 40.68 billion and 32% by 2034. Diagnostic and Monitoring Devices grows fastest at 8.19%, taking its share from 26% to 28%, while Surgical Devices grows slowest at 5.13%. The lines gaining share are Diagnostic and Monitoring Devices and Interventional Devices. Implantable Devices, Surgical Devices and External Support Devices lose share without losing revenue.

The application split puts Coronary Artery Disease (CAD) first, at USD 22.95 billion and 34% of revenue in 2025, rising to USD 40.68 billion and 32% in 2034. Heart Failure grows faster at 8.55% against 6.57%, moving from 18% of revenue to 20% by 2034. It cuts the same total as the devicetype axis from a different commercial angle, so revenue does not add across the two.

USD 26.33 billion of 2025 revenue is generated in North America, 39% of the global total and the largest regional share; it reaches USD 45.77 billion by 2034. Europe is next at 26% and USD 17.55 billion, and Middle East and Africa last at 5%. Because Asia Pacific take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

Behind these figures sit five regions, five devicetype lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies, short of a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.

• A forecast-period rate of 7.31% takes the market from USD 67.5 billion in 2025 to USD 127.13 billion in 2034, against 6.4% recorded over the 2020-2025 historical period.
• 30% of 2025 revenue sits in Interventional Devices (USD 20.25 billion) and it remains the largest devicetype line in 2034 at USD 40.68 billion and 32%.
• At 8.19%, Diagnostic and Monitoring Devices grows faster than any other devicetype line, moving from USD 17.55 billion and 26% of revenue in 2025 to USD 35.6 billion and 28% in 2034.
• Scenario range for 2034 runs from USD 115.69 billion in the bear case to USD 142.39 billion in the bull case, against a base-case USD 127.13 billion, the spread a plan built on this forecast has to absorb.
• The largest region is North America, generating USD 26.33 billion in 2025 (39% of the global total) and USD 45.77 billion by 2034, ahead of Europe at 26%.
• Within North America, the United States is the worked country example, at USD 22.38 billion in 2025; 85% of regional revenue in the base year, and USD 38.9 billion by 2034.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

The global cardiovascular devices market is shaped over 2026-2034 by three measurable movements: a change in the devicetype mix, a shift in where revenue sits geographically, and the 7.31% rate carrying the total.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

Diagnostic and Monitoring Devices grows faster than Surgical Devices. Diagnostic and Monitoring Devices grows at 8.19% across 2026-2034 against 5.13% for Surgical Devices, the widest spread on the devicetype axis. Shares follow: 26% to 28% for Diagnostic and Monitoring Devices, 12% to 10% for Surgical Devices. Neither contracts: USD 17.55 billion becomes USD 35.6 billion, USD 8.1 billion becomes USD 12.71 billion. What the spread decides is which of them a supplier's revenue is exposed to.

Regional weight shifts toward Asia Pacific. Asia Pacific moves from 24% of revenue in 2025 to 29% in 2034, worth USD 16.2 billion rising to USD 36.87 billion. Share moves off the others in turn: North America at 39% moving to 36%, Europe at 26% moving to 24%, Latin America at 6% moving to 6%, Middle East and Africa at 5% moving to 5%, each still growing in revenue terms. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

Fifteen years without a discontinuity. The market moves through USD 49.5 billion in 2020, USD 64.6 billion in 2024, USD 67.5 billion in 2025, USD 72.3 billion in 2026, USD 95.9 billion in 2030 and USD 127.13 billion in 2034. The forecast rate of 7.31% sits against 6.4% over the historical period, so the projection extends an observed trend instead of proposing a new one. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the devicetype and regional mixes matter more to a forecast than the headline rate does.

Diagnostic and Monitoring Devices adds the most incremental growth

Growth in the global cardiovascular devices market comes from three measurable sources over 2026-2034: the market's own compounding at 7.31%, the share gained by faster-growing devicetype lines, and expansion in the regions taking a larger part of global revenue.

What holds the forecast back

Where the forecast could be beaten

One devicetype line carries the market

North America holds 39% of the global cardiovascular devices market in 2025, worth USD 26.33 billion rising to USD 45.77 billion in 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

Its share moves to 36% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the devicetype split tracks the global one; 30% of 2025 revenue in Interventional Devices, fastest growth of 8.19% in Diagnostic and Monitoring Devices. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The largest single market in North America is the United States, at USD 22.38 billion in 2025 and USD 38.9 billion in 2034. 85% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. The region itself runs USD 26.33 billion to USD 45.77 billion over the same period, and this is the market carrying the country-level detail in the full report.

The devicetype pattern in the United States is the global one: 30% of 2025 revenue in Interventional Devices, 32% by 2034, against 8.19% growth in Diagnostic and Monitoring Devices taking it from 26% to 28%. Because the country carries 85% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-devicetype revenue for the United States appears on its own in the full report.

In the United States, the Food and Drug Administration regulates cardiovascular devices through its Center for Devices and Radiological Health, applying a risk-based classification framework of Class I, II, and III. Most cardiovascular implants and catheters fall into the higher-risk categories, requiring either full Premarket Approval, supported by clinical evidence, or clearance through the agency's substantial-equivalence notification pathway for lower-risk designs. Manufacturers must also operate under the FDA's Quality System Regulation, covering design controls and manufacturing practices, register their facilities, and list each device with the agency. Labelling must state intended use and warnings, and firms carry ongoing obligations for adverse event reporting and device identification after market entry.

B. Braun Melsungen AG (Melsungen, Germany), Medtronic (Dublin, Ireland), Abbott (Abbott Park, U.S.), Boston Scientific Corporation (Marlborough, U.S.), Edwards Lifesciences Corporation (Irvine, U.S.), Johnson & Johnson Services, Inc. (New Brunswick, U.S.), GENERAL ELECTRIC COMPANY (GE Healthcare) (Chicago, U.S.), LivaNova PLC (London, U.K.), Siemens Healthcare GmbH (Erlangen, Germany), Terumo Cardiovascular Systems Corporation (Tokyo, Japan) and Other Prominent Players are the suppliers covered in the United States. The commercially relevant division is 30% of 2025 revenue in Interventional Devices, where the volume is, against 8.19% growth in Diagnostic and Monitoring Devices, where share moves. The full report covers country-level positioning and shares company by company; this summary does not.

Canada is sized at USD 3.95 billion in 2025, rising to USD 6.87 billion by 2034; 5.85% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.

Europe holds 26% of the global cardiovascular devices market in 2025, worth USD 17.55 billion and reaches USD 30.51 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.

Share settles at 24% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The devicetype mix reported at global level applies here, with Interventional Devices the largest line at 30% of 2025 revenue and Diagnostic and Monitoring Devices the fastest-growing at 8.19%. Europe is reported axis by axis and country by country in the full study.

Germany is the largest market within Europe, generating USD 4.91 billion in 2025 and projected to reach USD 8.54 billion by 2034. At 28% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Set against USD 17.55 billion and USD 30.51 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Germany buys along the same lines as the market globally; Interventional Devices first at 30% of 2025 revenue and 32% in 2034, Diagnostic and Monitoring Devices fastest at 8.19% on a share moving from 26% to 28%. With 28% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Germany by devicetype separately.

Germany applies the European Union's Medical Device Regulation, which requires cardiovascular devices to undergo conformity assessment by an independent Notified Body before carrying the CE mark that permits sale across the bloc. Devices are classified by risk, with implantable and life-sustaining cardiovascular products placed in the highest categories and subject to the closest scrutiny of their technical documentation, clinical evaluation, and manufacturing quality system. The national competent authority, the Federal Institute for Drugs and Medical Devices, oversees market surveillance and vigilance reporting within Germany. Suppliers must maintain a unique device identifier, provide labelling and instructions in German, and continue monitoring device performance once the product is placed on the market.

B. Braun Melsungen AG (Melsungen, Germany), Medtronic (Dublin, Ireland), Abbott (Abbott Park, U.S.), Boston Scientific Corporation (Marlborough, U.S.), Edwards Lifesciences Corporation (Irvine, U.S.), Johnson & Johnson Services, Inc. (New Brunswick, U.S.), GENERAL ELECTRIC COMPANY (GE Healthcare) (Chicago, U.S.), LivaNova PLC (London, U.K.), Siemens Healthcare GmbH (Erlangen, Germany), Terumo Cardiovascular Systems Corporation (Tokyo, Japan) and Other Prominent Players are the suppliers covered in Germany. Interventional Devices, at 30% of 2025 revenue, is where the volume sits, and Diagnostic and Monitoring Devices, growing at 8.19%, is where position changes hands over the forecast period. A supplier weighted toward Europe is competing over a base of USD 17.55 billion in 2025 reaching USD 30.51 billion by 2034, 26% of global revenue at the start of that period.

Within Europe, the United Kingdom accounts for 22% of regional revenue and 5.72% of the global total, worth USD 3.86 billion in 2025 and USD 6.71 billion by 2034.

4.68% of global revenue is generated in France; USD 3.16 billion in 2025, reaching USD 5.49 billion in 2034, and 18% of Europe.

In Asia Pacific, 24% of global revenue puts 2025 at USD 16.2 billion and reaches USD 36.87 billion by 2034. Among the five regions it ranks third by revenue in both years.

By 2034 the share has moved up to 29%, so the region grows faster than the market's 7.31% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Within the region the devicetype split tracks the global one; 30% of 2025 revenue in Interventional Devices, fastest growth of 8.19% in Diagnostic and Monitoring Devices. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

The largest single market in Asia Pacific is China, at USD 5.67 billion in 2025 and USD 12.9 billion in 2034. 35% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 16.2 billion to USD 36.87 billion over the same period, and this is the market carrying the country-level detail in the full report.

China buys along the same lines as the market globally; Interventional Devices first at 30% of 2025 revenue and 32% in 2034, Diagnostic and Monitoring Devices fastest at 8.19% on a share moving from 26% to 28%. Because the country carries 35% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. China carries its own devicetype breakdown in the full report.

China's National Medical Products Administration governs the approval and oversight of cardiovascular devices, classifying them by risk into ascending tiers that determine the depth of review. Higher-risk cardiovascular implants and interventional devices generally require registration with the national authority, supported by clinical trial data generated within the country or accepted through bridging studies, along with mandatory testing at accredited domestic laboratories to confirm conformity with Chinese national standards. Imported devices must also secure a local licensed agent to handle registration and post-market responsibilities. Labelling and instructions must appear in Chinese, and manufacturers remain subject to ongoing inspection and adverse event reporting once a device reaches the market.

Competition in China runs between the suppliers this study tracks: B. Braun Melsungen AG (Melsungen, Germany), Medtronic (Dublin, Ireland), Abbott (Abbott Park, U.S.), Boston Scientific Corporation (Marlborough, U.S.), Edwards Lifesciences Corporation (Irvine, U.S.), Johnson & Johnson Services, Inc. (New Brunswick, U.S.), GENERAL ELECTRIC COMPANY (GE Healthcare) (Chicago, U.S.), LivaNova PLC (London, U.K.), Siemens Healthcare GmbH (Erlangen, Germany), Terumo Cardiovascular Systems Corporation (Tokyo, Japan) and Other Prominent Players. Two different problems sit on the same axis: holding Interventional Devices at 30% of 2025 revenue, and taking Diagnostic and Monitoring Devices while it grows at 8.19%. That makes Asia Pacific a 24% share of 2025 global revenue, USD 16.2 billion rising to USD 36.87 billion, for any supplier deciding where to concentrate.

5.27% of global revenue is generated in Japan; USD 3.56 billion in 2025, reaching USD 8.11 billion in 2034, and 22% of Asia Pacific.

Within Asia Pacific, India accounts for 15% of regional revenue and 3.6% of the global total, worth USD 2.43 billion in 2025 and USD 5.53 billion by 2034.

6% of the global cardiovascular devices market sits in Latin America in 2025, worth USD 4.05 billion on the way to USD 7.63 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

6% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Interventional Devices largest at 30% of 2025 revenue, Diagnostic and Monitoring Devices fastest at 8.19%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

Brazil is the largest market within Latin America, generating USD 1.82 billion in 2025 and projected to reach USD 3.43 billion by 2034. It accounts for 45% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 4.05 billion and USD 7.63 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Brazil buys along the same lines as the market globally; Interventional Devices first at 30% of 2025 revenue and 32% in 2034, Diagnostic and Monitoring Devices fastest at 8.19% on a share moving from 26% to 28%. With 45% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-devicetype revenue for Brazil appears on its own in the full report.

In Brazil, the National Health Surveillance Agency oversees the registration and control of cardiovascular devices, requiring a formal risk classification before any product can be marketed. Higher-risk implantable and interventional cardiovascular devices must undergo registration with the agency, supported by technical and clinical documentation, and manufacturers must hold Good Manufacturing Practice certification confirming that production facilities meet the agency's inspection standards. Devices already cleared by recognised foreign regulators can sometimes follow an expedited review, though the agency retains authority over the final decision. Labelling and instructions for use must appear in Portuguese, and companies must maintain a local registration holder responsible for post-market vigilance within the country.

The suppliers tracked in this study (B. Braun Melsungen AG (Melsungen, Germany), Medtronic (Dublin, Ireland), Abbott (Abbott Park, U.S.), Boston Scientific Corporation (Marlborough, U.S.), Edwards Lifesciences Corporation (Irvine, U.S.), Johnson & Johnson Services, Inc. (New Brunswick, U.S.), GENERAL ELECTRIC COMPANY (GE Healthcare) (Chicago, U.S.), LivaNova PLC (London, U.K.), Siemens Healthcare GmbH (Erlangen, Germany), Terumo Cardiovascular Systems Corporation (Tokyo, Japan) and Other Prominent Players) compete in Brazil across the devicetype lines above. Two different problems sit on the same axis: holding Interventional Devices at 30% of 2025 revenue, and taking Diagnostic and Monitoring Devices while it grows at 8.19%. That makes Latin America a 6% share of 2025 global revenue, USD 4.05 billion rising to USD 7.63 billion, for any supplier deciding where to concentrate.

Within Latin America, Mexico accounts for 30% of regional revenue and 1.81% of the global total, worth USD 1.22 billion in 2025 and USD 2.29 billion by 2034.

USD 3.37 billion of 2025 revenue is generated in Middle East and Africa, 5% of the global cardiovascular devices market with USD 6.35 billion projected for 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

Its share moves to 5% by 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the devicetype split tracks the global one; 30% of 2025 revenue in Interventional Devices, fastest growth of 8.19% in Diagnostic and Monitoring Devices. Middle East and Africa is reported axis by axis and country by country in the full study.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 1.01 billion in 2025 and USD 1.91 billion in 2034. At 30% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Regional revenue of USD 3.37 billion in 2025 and USD 6.35 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Saudi Arabia buys along the same lines as the market globally; Interventional Devices first at 30% of 2025 revenue and 32% in 2034, Diagnostic and Monitoring Devices fastest at 8.19% on a share moving from 26% to 28%. Its 30% weight in Middle East and Africa means those movements carry straight into the regional totals. The full report reports Saudi Arabia by devicetype separately.

In Saudi Arabia, the Saudi Food and Drug Authority regulates cardiovascular devices through its Medical Devices National Registry, requiring manufacturers to classify products by risk and register them before distribution. The framework draws heavily on international benchmarks, including guidance from the International Medical Device Regulators Forum and Gulf-wide harmonisation efforts among Gulf Cooperation Council states, so conformity already established under a recognised foreign regulatory system can support the local registration file. Authorised local representatives must be appointed to manage registration and communicate with the authority on behalf of foreign manufacturers. Labelling must appear in Arabic alongside English, and suppliers remain responsible for reporting adverse events and maintaining quality management practices after a device enters the market.

In Saudi Arabia the field is B. Braun Melsungen AG (Melsungen, Germany), Medtronic (Dublin, Ireland), Abbott (Abbott Park, U.S.), Boston Scientific Corporation (Marlborough, U.S.), Edwards Lifesciences Corporation (Irvine, U.S.), Johnson & Johnson Services, Inc. (New Brunswick, U.S.), GENERAL ELECTRIC COMPANY (GE Healthcare) (Chicago, U.S.), LivaNova PLC (London, U.K.), Siemens Healthcare GmbH (Erlangen, Germany), Terumo Cardiovascular Systems Corporation (Tokyo, Japan) and Other Prominent Players. Volume sits in Interventional Devices at 30% of 2025 revenue; movement sits in Diagnostic and Monitoring Devices at 8.19% growth. The commercial size of that position is USD 3.37 billion in 2025 and USD 6.35 billion by 2034, 5% of the global total in the base year.

1.1% of global revenue is generated in South Africa; USD 0.74 billion in 2025, reaching USD 1.4 billion in 2034, and 22% of Middle East and Africa.

The United Arab Emirates is sized at USD 0.61 billion in 2025, rising to USD 1.14 billion by 2034; 0.9% of global revenue and 18% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by devicetype, application, end-user, procedure type, distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.